Plasma Acylcarnitines and Amino Acids in Dyslipidemia: An Integrated Metabolomics and Machine Learning Approach Publisher



Etemadi A^{1, 2} ; Hassanzadehkiabi F² ; Mirabolghasemi M³ ; Ahmadi M² ; Dehghanbanadaki H⁴ ; Hosseinkhani S⁵ ; Bandarian F¹ ; Najjar N⁵ ; Dilmaghanimarand A⁶ ; Panahi N⁵ ; Negahdari B² ; Mazloomi M² ; Karimijafari MH³ ; Razi F¹ Show All Authors Show Affiliations
Source: Journal of Diabetes and Metabolic Disorders Published:2024

Abstract

Purpose: The Discovery of underlying intermediates associated with the development of dyslipidemia results in a better understanding of pathophysiology of dyslipidemia and their modification will be a promising preventive and therapeutic strategy for the management of dyslipidemia. Methods: The entire dataset was selected from the Surveillance of Risk Factors of Noncommunicable Diseases (NCDs) in 30 provinces of Iran (STEPs 2016 Country report in Iran) that included 1200 subjects and was stratified into four binary classes with normal and abnormal cases based on their levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and non-HDL-C. Plasma concentrations of 20 amino acids and 30 acylcarnitines in each class of dyslipidemia were evaluated using Tandem mass spectrometry. Then, these attributes, along with baseline characteristics data, were used to check whether machine learning (ML) algorithms could classify cases and controls. Results: Our ML framework accurately predicts TG binary classes. Among the models tested, the SVM model stood out, performing slightly better with an AUC of 0.81 and a standard deviation of test accuracy at 0.04. Consequently, it was chosen as the optimal model for TG classification. Moreover, the findings showed that alanine, phenylalanine, methionine, C3, C14:2, and C16 had great power in differentiating patients with high TG from normal TG controls. Conclusions: The comprehensive output of this work, along with sex-specific attributes, will improve our understanding of the underlying intermediates involved in dyslipidemia. © The Author(s), under exclusive licence to Tehran University of Medical Sciences 2024.